Stock Screener App

無料 -

インストール

Medical Devices

70.60

2.02% 1.40

after-market

アフターアワーズ： 70.60

Edwards Lifesciences Corp (EW)

概要ニュース株価時系列オプションチェーン Financials なぜEWが下落しているのか？ディスカッション予測株式分割

Edwards Lifesciences Corp (EW) 最新ニュース

Edwards touts 8-year data for Resilia valve tissue - MassDevice

Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance

Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus

Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan

Is Edwards Lifesciences Gaining or Losing Market Support? - Benzinga

Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com

Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - marketscreener.com

Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com Australia

Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - BioSpace

Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa

Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech

Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - MarketScreener

Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener

Edwards wins CE mark for Sapien M3 transfemoral heart valve - MassDevice

Breakthrough: First-Ever Transcatheter Mitral Valve Replacement Gets CE Mark Approval - Stock Titan

Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - marketscreener.com

Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga

Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - marketscreener.com

Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq

Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com

Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock By Investing.com - Investing.com Canada

Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock - Investing.com

CMS rolls out draft coverage memo for TEER for the tricuspid valve - BioWorld MedTech

Citigroup Adjusts Edwards Lifesciences Price Target to $84 From $83, Maintains Buy Rating - MarketScreener

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar

Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session - Yahoo Finance

Edwards’ Early TAVR refutes surveillance recs for aortic stenosis - BioWorld MedTech

Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Home

Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now! - Insider Monkey

Edwards shares data supporting timely TAVR intervention - MassDevice

Huntington Beach man meets heart valve engineers who saved his life - Los Angeles Times

Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener

Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener

Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com

Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock By Investing.com - Investing.com South Africa

Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha

S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN

How Is The Market Feeling About Edwards Lifesciences? - Benzinga

Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq

Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart

Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN

Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia

Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com

GEHC

$61.65

1.93%

DXCM

$66.33

0.33%

STE

$222.77

1.82%

PHG

$24.14

3.65%

ZBH

$97.44

1.32%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く